HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (1- cinnamyl- 1H- 1,2,3- triazol- 4- yl)- N- hydroxyacrylamide

structure in first source

Also Known As:

NSC 746457; NSC-746457; NSC746457

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - 3-(1-cinnamyl-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 1
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - 3-(1-cinnamyl-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - 3-(1-cinnamyl-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide: 1

Experts

1.	Chen, Min: 1 article (12/2008)
2.	Fang, Lanyan: 1 article (12/2008)
3.	Kedenburg, James Patrick: 1 article (12/2008)
4.	Liu, Xianwei: 1 article (12/2008)
5.	Shen, Jie: 1 article (12/2008)
6.	Sun, Duxin: 1 article (12/2008)
7.	Wang, Peng George: 1 article (12/2008)
8.	Woodward, Robert: 1 article (12/2008)

Related Diseases

1.

Neoplasms (Cancer)

12/11/2008 - "A lead compound 5 g (NSC746457) was discovered that inhibited HDAC1 at an IC(50) value of 104 +/- 30 nM and proved quite potent in the cancer cell line screen with GI(50) values ranging from 3.92 microM to 10 nM. Thus, this click HDACi design has provided a new chemical scaffold that has not only revealed a lead compound, but one which is easily amendable to further structural modifications given the modular nature of this approach."